Injectable and Finished Product Services Market Size, Share, Growth, Trends, and Global Industry Analysis: By Molecule Type (Small Molecule, and Biologics), By Product Type (Small Volume Products, Large Volume Products, Lyophilized Products, and Others), By Disease Indication (Cardiometabolic Diseases, Nephrological Diseases, Neurological Diseases, Respiratory Diseases, Infectious Diseases, Rare Diseases, Cancer, and Others), By Type of Products (Monoclonal Antibodies, Peptide Antibiotics, Chemical Entities, Gene Therapy, Cell Therapy, Hormones, Vaccines, mRNA, and Others), By End User (Pharma and Biopharma (Small and Start-ups, Mid-Size, and Large Companies)), and Region Forecast 2020-2031

Injectable and Finished Product Services Market size was valued at US$ 688.3 billion in 2024 and is expected to reach US$ 981.5 billion by 2031, growing at a significant CAGR of 5.2% from 2025-2031. The market is rapidly expanding, fueled by the increasing adoption of biologics, personalized therapies, and advanced drug delivery systems. In 2024, the U.S. FDA approved 16 biologics, accounting for 32% of all new drug approvals, highlighting the growing reliance on injectable formats for complex therapeutics. The approval of Pfizer’s Beqvez, a gene therapy for hemophilia B, in April 2024 underscores the demand for specialized sterile fill-finish services capable of handling high-value, sensitive biologics.

Leading pharmaceutical companies like Eli Lilly are ramping up production of high-demand injectables, such as Zepbound (for obesity), by partnering with CDMOs like National Resilience and BSP Pharmaceuticals to expand sterile fill-finish capacity. Despite this growth, the market faces challenges, including high infrastructure costs, stringent regulatory compliance, and the need for aseptic manufacturing environments. Nevertheless, advances in single-use systems, robotics, and automation improve process efficiency, reduce cross-contamination risks, and enable faster turnaround.

In addition, trends like ready-to-administer formats and self-injectable delivery systems are improving patient adherence and reshaping delivery models. These developments position injectable and finished product services as a critical pillar in the biopharmaceutical value chain.

Facts and Figures

• Eli Lilly invested over $20 billion since 2020 to expand manufacturing capabilities for injectable drugs like Mounjaro and Zepbound, responding to rising demand
• Novo Nordisk allocated $4 billion to enhance U.S. production of obesity and diabetes treatments, including Wegovy and Ozempic.

Key Takeaways

• More than 40% of FDA-approved medications are injectables, with increasing approvals for subcutaneous and intramuscular formulations.
• Growth in this sector is fueled by the adoption of biologics and biosimilars, as well as innovations in self-administration devices like autoinjectors and wearable injectors.
• Indian pharmaceutical companies are expanding into complex injectable generics, including liposomal and microsphere-based formulations, to differentiate themselves and tap into high-margin opportunities

Key Developments:

• In March 2025, Avenacy has launched five injectable antibiotics in the U.S., Ampicillin, Ampicillin/Sulbactam, Nafcillin, Penicillin G Potassium, and Piperacillin/Tazobactam capturing a $175M market opportunity. With differentiated packaging and strong cGMP-compliant partners, Avenacy aims to expand its presence in hospitals and home care, showcasing its portfolio at DCAT Week 2025.
• In December 2024, Baxter International launched five new injectable pharmaceutical products in the U.S., expanding its portfolio in critical care, oncology, and anti-infectives. The launches include Micafungin, Cyclophosphamide, Pantoprazole Sodium, Cefazolin, and Levetiracetam, with ready-to-use formulations offering operational efficiencies and enhanced patient safety.
• In January 2024, Amneal Pharmaceuticals launched 39 new products in 2023, up from 26 in 2022, including 13 in Q4 alone. Five were injectables like potassium phosphate vials and tranexamic acid. These innovations strengthen Amneal’s injectable portfolio and highlight its focus on complex, high-value generics to expand access to affordable medications.
• In January 2024, Piramal Critical Care has launched a new 10mg/10mL Zinc Sulfate Injection in the U.S., expanding its injectable portfolio. The pediatric-friendly formulation adds to existing strengths and complements recent launches like Pantoprazole and Doxycycline injections, reinforcing Piramal Pharma's presence in the global generic injectables and critical care market.

Injectable and Finished Product Services Market Segmentation:

Based on the Molecule Type:

• Small Molecule
• Biologics

The Biologics segment is a dominating force in the market. Biologics, including monoclonal antibodies, gene therapies, and vaccines, are driving significant growth due to their increasing use in treating complex diseases like cancer, autoimmune disorders, and genetic conditions. Their high efficacy and specificity continue to fuel demand.

Based on the Product Type:

• Small Volume Products
• Large Volume Products
• Lyophilized Products
• Others

The Small Volume Products segment dominates the market due to their widespread use in delivering high-potency drugs, including biologics and vaccines. These products, often administered through pre-filled syringes or auto-injectors, offer precise dosing and convenience, particularly for chronic disease treatments and emergency care.

Based on the Disease Indication:

• Cardiometabolic Diseases
• Nephrological Diseases
• Neurological Diseases
• Respiratory Diseases
• Infectious Diseases
• Rare Diseases
• Cancer
• Others

The Cancer segment is a dominant force in the market. With the increasing global cancer burden, the demand for injectable cancer treatments, including chemotherapy, targeted therapy, and immunotherapy, is growing. This segment is fueled by advancements in personalized medicine and biologic therapies, which require specialized injectable formulations.

Based on the Type of Product:

• Monoclonal Antibodies
• Peptide Antibiotics
• Chemical Entities
• Gene Therapy
• Cell Therapy
• Hormones
• Vaccines
• mRNA
• Others

Monoclonal antibodies (mAbs) are one of the dominating segments in the market. Their ability to target specific cells or proteins has made them essential in treating diseases like cancer, autoimmune disorders, and infectious diseases. The growing demand for mAb-based therapies continues to drive market growth.

Based on the End User:

• Pharma and Biopharma
  • Small and Start-ups
  • Mid-Size
  • Large Companies

The Pharma and Biopharma segment, particularly Large Companies, dominates the market. These companies leverage advanced manufacturing technologies, robust R&D capabilities, and global distribution networks to drive market growth. Their established market presence and significant investments in biologics and injectables make them key players in the sector.